SynBioBeta Speaker
Luis Cascão Pereira
IFF Health & Biosciences
Head of R&D Ventures & Digital Biology
Leading R&D Ventures and Digital Biology at IFF, building a global portfolio of TechBio platforms from discovery through commercialization. I focus on scaling AI‑enabled biology where industrial reality matters, linking prediction to manufacturing to deliver revenue acceleration, margin expansion, and access to novel molecules previously impossible to produce at scale.I lead the evolution of IFF’s Lab‑in‑a‑Loop platform, integrating AI, protein engineering, and bioprocessing to translate breakthrough science into durable businesses. My role spans platform strategy, external partnerships, and strategic M&A, acquiring critical AI/ML, synthetic biology, talent, and manufacturing capabilities. Core thesis: biology only scales when economics, sustainability, and user value align.Previously, I led global enzyme, strain, and bioprocess programs across four continents, delivering 40+ technology transfers and 13 commercial products, including one of the highest‑tonnage engineered enzymes ever commercialized. I also led the enzyme platform for the $225M DuPont cellulosic ethanol FOAK biorefinery.I advise startups, investors, and U.S. government and National Labs. PhD in Biochemical Engineering (UC Berkeley), Harvard Business School alumnus, 36 patents, JBEI Board member, and UC Berkeley guest lecturer.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Luis
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
